Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in combination with Fulvestrant, for women with advanced breast cancer. The drug will be available to NHS patients through the Cancer Drugs Fund (CDF).
The treatment could be an option for as many as 4,800 women who have already had endocrine treatment for hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.